MRK vs DVA
By Alex · Tickerpine
Merck & Co., Inc. vs DaVita Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | DVA |
|---|---|---|
| Price | $147.76 | $174.56 |
| Market cap | $364.26B | $10.98B |
| P/E ratio | 149.3 | 13.2 |
| ROE | 5.06% | 96.79% |
| Profit margin | 3.64% | 6.49% |
| Revenue growth | 4.70% | 4.60% |
| Dividend yield | 2.30% | 0.00% |
| Beta | 0.12 | 0.86 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs DVA in plain English
- MRK is the bigger company — about 33.2× the market cap of DVA.
- DVA is cheaper on earnings (P/E 13.2 vs 149.3).
- DVA earns a higher return on equity (97% vs 5%).
- MRK is growing revenue faster (5% vs 5%).
- MRK pays a dividend (2.30%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
DVA return calculator
See what $1,000 in DaVita Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.